Related Experiment Video

Updated: Aug 11, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Cyclooxygenase-2 inhibition and gastric cancer

Xiao Hua Jiang1, Benjamin C Y Wong

  • 1Department of Medicine, University of Hong Kong, Hong Kong. bcywong@hku.hk

Current Pharmaceutical Design
|October 8, 2003
PubMed

Insights

Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce gastric cancer risk. Cyclooxygenase-2 (COX-2) inhibitors show promise in preventing and treating pre-cancerous lesions and gastric cancer.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Epidemiological studies link NSAID use to reduced gastrointestinal cancer risk.
  • Gastric lesions and cancers overexpress cyclooxygenase-2 (COX-2).
  • COX-2 overexpression correlates with Helicobacter pylori infection and carcinogen exposure.

Purpose of the Study:

  • To explore the role of COX-2 inhibition in gastric cancer prevention and treatment.
  • To review COX-dependent and COX-independent mechanisms of action.
  • To discuss the therapeutic potential of COX-2 inhibitors.

Main Methods:

  • Review of epidemiological evidence.
  • In vitro studies on gastric cancer cell lines.
  • Analysis of animal xenograft models.
  • Discussion of ongoing human clinical trials.

Main Results:

  • Targeted COX-2 inhibition induces growth inhibition and apoptosis in gastric cancer cells.
  • COX-2 inhibitors demonstrate tumor-suppressing effects in animal models.
  • Human studies are evaluating COX-2 inhibitors for pre-cancerous lesion treatment.

Conclusions:

  • COX-2 inhibitors hold significant promise for gastric cancer prevention.
  • Targeting COX-2 offers a potential therapeutic strategy for pre-cancerous gastric lesions.
  • Further research and clinical trials are warranted to confirm the efficacy of COX-2 inhibitors in gastric cancer management.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...